The overall goal of this Program is to improve the survival of cancer patients by active specific immunotherapy. To achieve this goal we will utilize melanoma as a model neoplasm. This renewal application represents a continuation of our previous studies with polyvalent melanoma cell vaccine (PMCV) and investigates the in vivo and in vitro mechanisms of PMCV anti-cancer activity. Project 1 will evaluate the role of humoral immune responses to PMCV. Antigens that elicit immune responses to PMCV. Antigens that elicit immune responses in man will be studied following the development of human monoclonal antibodies. The study will determine which antigens are associated with disease regression by active specific immunotherapy. Project II will utilize several established assays to determine their utility as prognostic markers in patients receiving active specific immunotherapy, chemobiotherapy and/or surgery. Patients treated in Project III will receiving active specific immunotherapy, chemobiotherapy and/or surgery. Patients treated in Project III will serve as the study population for specimen procurement and the determination of clinical outcome. Project III has recently completed Phase I and II clinical trials, and has proven that the PMCV is safe and can significantly prolong the disease- free and overall survival of patients with high-risk melanoma in comparison to control patients treated at John Wayne Cancer Institute. In the renewal application, Project III will assess PMCV in Phase III randomized multicenter trial. Additionally, the Project will improve upon current immunological and biological stratification. The execution of these three projects relies on the support of four core components: Clinical Support Services, Biostatistics, Serum, Lymphocyte and Tissue Collection and Analysis, and Quality Services.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA012582-29
Application #
6149984
Study Section
Subcommittee G - Education (NCI)
Program Officer
Wu, Roy S
Project Start
1977-07-01
Project End
2002-01-31
Budget Start
2000-02-10
Budget End
2001-01-31
Support Year
29
Fiscal Year
2000
Total Cost
$6,155,521
Indirect Cost
Name
John Wayne Cancer Institute
Department
Type
DUNS #
556074458
City
Santa Monica
State
CA
Country
United States
Zip Code
90404
Dükel, Muzaffer; Streitfeld, W Scott; Tang, Tsz Ching Chloe et al. (2016) The Breast Cancer Tumor Suppressor TRIM29 Is Expressed via ATM-dependent Signaling in Response to Hypoxia. J Biol Chem 291:21541-21552
Kiyohara, Eiji; Hata, Keisuke; Lam, Stella et al. (2014) Circulating tumor cells as prognostic biomarkers in cutaneous melanoma patients. Methods Mol Biol 1102:513-22
Greenberg, Edward S; Chong, Kelly K; Huynh, Kelly T et al. (2014) Epigenetic biomarkers in skin cancer. Cancer Lett 342:170-7
Chiu, Connie G; Nakamura, Yoshitaka; Chong, Kelly K et al. (2014) Genome-wide characterization of circulating tumor cells identifies novel prognostic genomic alterations in systemic melanoma metastasis. Clin Chem 60:873-85
Faries, Mark B; Steen, Shawn; Ye, Xing et al. (2013) Late recurrence in melanoma: clinical implications of lost dormancy. J Am Coll Surg 217:27-34; discussion 34-6
Kidner, Travis B; Morton, Donald L; Lee, Delphine J et al. (2012) Combined intralesional Bacille Calmette-Guérin (BCG) and topical imiquimod for in-transit melanoma. J Immunother 35:716-20
Hoshimoto, Sojun; Shingai, Tatsushi; Morton, Donald L et al. (2012) Association between circulating tumor cells and prognosis in patients with stage III melanoma with sentinel lymph node metastasis in a phase III international multicenter trial. J Clin Oncol 30:3819-26
Hoshimoto, Sojun; Kuo, Christine T; Chong, Kelly K et al. (2012) AIM1 and LINE-1 epigenetic aberrations in tumor and serum relate to melanoma progression and disease outcome. J Invest Dermatol 132:1689-97
Faries, Mark B; Morton, Donald L (2012) Staging of regional nodes in pulmonary malignancies. Ann Surg Oncol 19:703-5
Hoshimoto, Sojun; Faries, Mark B; Morton, Donald L et al. (2012) Assessment of prognostic circulating tumor cells in a phase III trial of adjuvant immunotherapy after complete resection of stage IV melanoma. Ann Surg 255:357-62

Showing the most recent 10 out of 238 publications